doxorubicin encapsulated nanocells (EGFREDVDox) / EnGeneIC - LARVOL DELTA

CerebralEDV: A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Engeneic Pty Limited | Unknown status ➔ Completed | N=20 ➔ 9

Enrollment change • Trial completion • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Oncology • Solid Tumor